Egalet launches Acura's Oxaydo in U.S.

PALATINE - Acura Pharmaceuticals announced Egalet Corporation has commercially launched Oxaydo tablets, a product Egalet licensed from Acura, in the United States.

Oxaydo, an immediate release oxycodone hydrochloride formulation that incorporates Acura's patented Aversion (abuse-deterrent) technology, is indicated for the treatment of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

Oxaydo can be taken without regard to food, the way opioids generally are taken.

"We are excited that Oxaydo, for the first time, is being promoted to physicians by a pharmaceutical sales force," said Bob Jones, President and CEO of Acura. "Our marketing partner, Egalet, has done a terrific job building their commercial infrastructure to make this launch happen."

Acura's Aversion technology is a patented mixture of gelling ingredients and nasal irritants designed to address common forms of opioid abuse.

Acura's license agreement with Egalet provides for a payment of $2.5 million upon the first commercial sale of Oxaydo in the U.S., which Acura currently expects to receive in the fourth quarter of 2015, and an additional one-time payment of $12.5 million when annual worldwide net sales of Oxaydo first reach $150 million in a calendar year. Acura is also to receive a stepped royalty at percentage rates from mid-single digits to double digits based on the level of Oxaydo worldwide net sales in a calendar year (including any product line extensions). Royalties are payable on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of Acura's patent in such country.